GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 9 [US20230119327A1]
Compound class:
Synthetic organic
Comment: The chemical structure for atebimetinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as a MEK tyrosine kinase inhibitor with antineoplastic potential. The structure is claimed in patent US20230119327A1 (Immuneering Corp) [1]. Immuneering have a MEK inhibitor called IMM-1-104 as a lead asset in their development pipeline. IMM-1-104 is designed to inhibit MEK and ERK phosphorylation downstream of RAS, to achieve robust MAPK pathway inhibition irrespective of the oncogenic RAS mutation present in the tumour.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| N-({4-[(dimethylamino)methyl]-3-({2-fluoro-3-[(methylsulfamoyl)amino]phenyl}methyl)-2-oxo-2H-chromen-7-yl}methyl)-N-methylcarbamate |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 13383 | atebimetinib |
Synonyms ![]() |
| compound 9 [US20230119327A1] |
Database Links ![]() |
|
| CAS Registry No. | 2669009-92-9 (source: WHO INN record) |
| GtoPdb PubChem SID | 513757515 |
| PubChem CID | 168111901 |
| Search Google for chemical match using the InChIKey | QIMAJRSGTYJBIS-UHFFFAOYSA-M |
| Search Google for chemicals with the same backbone | QIMAJRSGTYJBIS |
| Search PubMed clinical trials | atebimetinib |
| Search PubMed titles | atebimetinib |
| Search PubMed titles/abstracts | atebimetinib |
| UniChem Compound Search for chemical match using the InChIKey | QIMAJRSGTYJBIS-UHFFFAOYSA-M |
| UniChem Connectivity Search for chemical match using the InChIKey | QIMAJRSGTYJBIS-UHFFFAOYSA-M |